Last Updated on March 12, 2025 by The Health Master
Rule 89
Rule 89: The Government of India to refine regulations for manufacturing of drugs, specially related to the testing of drugs, i.e., vaccines, antibiotics and critical biologics.
This move, driven by the Central Drugs Consultative Committee (DCC), aims to bring much-needed clarity to the existing Drugs Rules, 1945.
The proposal of the said amendments will target the loan license procedures which may faster the licensing process with more transparency.
Addressing the Form 29 Amendment
Currently, Rule 89 of the Drugs Rules, 1945, dictates the issuance of Form 29 licenses for manufacturing drugs solely for examination, testing, or analysis.
However, a particular gap exists when these drugs fall under categories like vaccines, antibiotics and biologics for which there is a requirements for various forms e.g., Form 25A, 28A, and 28DA.
This has led to regulatory ambiguity and potential hurdles for manufacturers.
Understanding the Forms:
Form 25A: Loan 1[licence to manufacture for sale or for distribution of] drugs other than those specified In 2[Schedules C and C (1) and X].
Form 28A: Loan 1[Licence to manufacture for sale or for distribution of] drugs specified in Schedules C and C (1) 2[excluding those specified in Schedule X].
Form 28DA: Loan licence to manufacture for sale or for distribution of Large Volume Parenterals/Sera and Vaccines/recombinant DNA (r-DNA) derived drugs excluding those specified in Schedule X.
Form 29: Licence to manufacture drugs for purposes of examination, test or analysis.
The DCC has given its recommendations to amend the Drugs Rules to include provisions for Form 29 licenses in these specialized cases.
This amendment will ensure that loan licensees can obtain the necessary approvals for testing and analysis of biologics, vaccines, and antibiotics without facing procedural roadblocks.
The DCC also recommended that the Form 29 license must be site-specific and the stringent quality control must be there.
This clarity can help in streamlining the drug development timelines.
Ensuring Accountability: Batch Release and Authorized Personnel
Beyond the Form 29 amendment, the DCC has also proposed adding the name of the authorized person responsible for batch release to all manufacturing licenses and batch release certificates.
This has been done for the purpose of enhancing transparency and accountability in the manufacturing process of drugs.
Why This Important:
Current manufacturing licenses (Forms 25, 25A, etc.) only list the competent technical staff for manufacture and testing.
Batch release, a critical step, lacks explicit identification of the responsible individual.
It will strengthen traceability and quality assurance if this information is included.
The DCC has forwarded this recommendation to the Drugs Technical Advisory Board (DTAB) for further line of action.
This change addresses the very important process i.e., batch release, which is integral to the safety and efficacy of drugs.
This could lead to an increase in demand for pharmaceutical quality control services.
Addressing Safety Concerns: High-Risk Drugs
The existing Rule 89 also stipulates that for drugs not generally recognized as safe by experts, a certificate from the licensing authority is required before granting a Form 29 license.
This provision will ensure stringent scrutiny of the high-risk drugs, before the testing or analysis.
Q. What is a Form 29 license?
A. Form 29 license allows manufacturers to produce drugs solely for examination, testing, or analysis.
Q. Why is the government amending the Drugs Rules?
A. The govt is amending the Drugs Rules to address various regulatory ambiguity and for clarity in the licensing process for vaccines, antibiotics and biologics.
Q. What is the significance of including the authorized person for batch release?
A. It enhances accountability and traceability in the drug manufacturing process, ensuring quality and safety.
Q. What are Biologics?
A. Biologics are medical products made from living organisms or contain components of living organisms. They include vaccines, blood, blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
Q. What are the benefits of loan licensing?
A. Loan licensing allows companies that do not have their own manufacturing facilities to produce drugs by utilizing the facilities of another licensed manufacturer. This can reduce startup costs and increase efficiency.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Cosmetic Labels: DCC suggests BIS Standards
Boosting Drug Regulatory Efficiency: DCC recommends for Training and Development
DCC: A Call for Safe and Responsible Drug Disposal
DCC recommends amendment of Rules to curbing Antimicrobial Resistance
DCC recommends closely monitoring quality of Eye Drops
DCC recommends to address drug Brand Name Confusion in India
DCC: Take action to Curb Antimicrobial Resistance (AMR) in India
Gujarat Drug Inspectors Armed with Spectrophotometers for Instant Drug Tests
FDA Punjab to track manufacture and sale of these 7 drugs
OTC Medicines list coming this month: India
Drug recall: Glenmark recalls 15 lakh bottles of this Drug
Karnataka’s new NSQ Drug Recall Policy
New Drug Approval: DCGI Demands Uniformity
FSSAI: Food Labelling and Display – Chapter-15
Workshop on NDPS to combat the misuse of drugs: FDA Haryana
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
